Design Therapeutics shares Phase 1/2 data in Friedreich ataxia; Vincentage Pharma, a new China obesity player, emerges with Phase 3 data; Roche’s Tecentriq secures another US approval for bladder cancer; Enhertu wins label expansion for two early breast cancer indications
Plus, news about Enhertu and Tecentriq.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Confirm Endpoints as a trusted biopharma news source
Bioscience & Technology Business Center
The University of Kansas
BeOne wins FDA approval in lymphoma race
Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod
The Oral GLP-1 Tracker: Wegovy pill total scripts down for first time
FDA floats possible approach to repurpose approved drugs under new uses
Regulatory tracker: Taiho's Inqovi widens its reach with FDA label expansion
Market News – Business Wire | Morningstar
